Updated Consensus Provides New Roadmap for Managing Childhood Bed-Wetting

Nocturnal enuresis (NE), commonly known as bed-wetting, affects a significant number of school-age children and can have profound effects on self-esteem, sleep, and family dynamics. An updated expert consensus, published in the World Journal of Pediatrics, now provides a comprehensive framework for the diagnosis, classification, and management of this condition. The new guidance includes 18 recommendations that aim to shift clinical practice from symptom-based treatment to more standardized, individualized, and family-centered care.

One of the key updates is the lowered diagnostic threshold: children aged five years or older who experience at least one involuntary nighttime void per month for three months now qualify for a diagnosis of NE. This is a change from the previous standard of weekly episodes, allowing for earlier intervention. The consensus also mandates a clear distinction between monosymptomatic enuresis (MNE), where no daytime lower urinary tract symptoms (LUTS) are present, and non-monosymptomatic enuresis (NMNE), which involves daytime symptoms such as urgency, frequency, or incontinence. This classification is crucial for guiding treatment decisions.

The voiding diary has become a cornerstone of diagnosis, requiring patients to record at least two daytime charts and seven consecutive nights of fluid intake and voids. This allows clinicians to phenotype children as having nocturnal polyuria, reduced bladder capacity, or both. For MNE, the consensus recommends phenotype-driven first-line therapy: desmopressin for nocturnal polyuria and the enuresis alarm for reduced bladder capacity, with combination therapy for mixed types. For NMNE, management must first address daytime LUTS and comorbidities, especially constipation, which affects 36–80% of these children, before tackling nighttime wetting.

The framework also outlines clear referral criteria. Primary care providers can manage MNE, but non-responders or suspected NMNE cases require specialist evaluation with urodynamics and lumbosacral magnetic resonance imaging (MRI). For refractory cases, defined as less than 50% improvement after three months, the consensus advises systematic re-evaluation of adherence, diary findings, and underlying causes before escalating treatment.

The authors emphasize that NE should not be treated as a single, uniform disorder. Instead, clinicians should identify the child's specific pattern, look for daytime symptoms and comorbidities, and match treatment to the likely underlying mechanism while involving the family. They also stress that apparent treatment failure should prompt a careful review of adherence, voiding records, and possible missed conditions before adding stronger therapy.

In practice, these recommendations could help pediatricians and primary-care clinicians determine which children can be managed locally and which need specialist assessment. Clearer use of voiding diaries and symptom-based classification may reduce trial-and-error treatment, while earlier attention to constipation, sleep-disordered breathing, ADHD, and daytime urinary symptoms could improve response rates. The framework also encourages timely referral when first-line therapy fails or NMNE is suspected, supporting better coordination across levels of care.

The authors acknowledge that some recommendations reflect Chinese practice patterns and that evidence remains limited for certain areas, such as desmopressin withdrawal strategies. Future trials and multidisciplinary care models could further refine individualized treatment approaches. The full consensus is available in the World Journal of Pediatrics with DOI: 10.1007/s12519-026-01051-4.